Recombinant Vaccinia virus-coded interferon inhibitor B18R: Expression, refolding and a use in a mammalian expression system with a RNA-vector

PLoS ONE

Volumn 12, Issue 12, 2017, Pages

  Kim, Yuriy G ^a   Baltabekova, Aliya Zh ^b   Zhiyenbay, Erzhan E ^a   Aksambayeva, Altynai S ^b   Shagyrova, Zhadyra S ^b   Khannanov, Rinat ^b   Ramanculov, Erlan M ^a   Shustov, Alexandr V ^b  

^a NAZARBAYEV UNIVERSITY   (Kazakhstan)

^b NATIONAL CENTER FOR BIOTECHNOLOGY   (Kazakhstan)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; POXVIRUS VECTOR; PROTEIN B18R; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; RECOMBINANT VACCINIA VIRUS CODED INTERFERON INHIBITOR B18R; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS RNA; B18R PROTEIN, VACCINIA VIRUS;

ARTICLE; BIOLOGICAL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; MAMMALIAN EXPRESSION SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN REFOLDING; PROTEIN SYNTHESIS; REPLICON; RNA REPLICATION; RNA VECTOR; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS GENOME; VIRUS REPLICATION; CHEMISTRY; GENE VECTOR; GENETICS; HEK293 CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN FOLDING; SIZE EXCLUSION CHROMATOGRAPHY; VACCINIA VIRUS;

CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENETIC VECTORS; HEK293 CELLS; HUMANS; PROTEIN FOLDING; RECOMBINANT PROTEINS; RNA, VIRAL; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 85037344845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0189308     Document Type: Article

References (44)

1. Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc SN. 2007; 5:1236–1247.
2. Schott JW, Hoffmann D, Schambach A. Retrovirus-based vectors for transient and permanent cell modification. Curr Opin Pharmacol. 2015; 24:135–146. https://doi.org/10.1016/j.coph.2015.09.004 PMID: 26433198
3. Farazmandfar T, Khanahmad SH, Haghshenas MR, Janbabai G, Azadeh H, Mansour Samaei N. Use of integrase-minus lentiviral vector for transient expression. Cell J. 2012; 14:76–81. PMID: 23508124
4. Kremer M, Volz A, Kreijtz JH, Fux R, Lehmann MH, Sutter G. Easy and efficient protocols for working with recombinant vaccinia virus MVA. Methods Mol Biol. 2012; 890:59–92. https://doi.org/10.1007/978-1-61779-876-4_4 PMID: 22688761
5. Lackner A, Kreidl E, Peter-Vorosmarty B, Spiegl-Kreinecker S, Berger W, Grusch M. Stable protein expression in mammalian cells using baculoviruses. Methods Mol Biol. 2012; 801:75–92. https://doi.org/10.1007/978-1-61779-352-3_6 PMID: 21987248
6. Aranda A, Ruiz-Guillen M, Quetglas JI, Bezunartea J, Casales E, Smerdou C. Recent patents on alphavirus protein expression and vector production. Recent Pat Biotechnol. 2011; 5:212–226. PMID: 22360469
7. Casales E, Aranda A, Quetglas JI, Ruiz-Guillen M, Rodriguez-Madoz JR, Prieto J, et al. A novel system for the production of high levels of functional human therapeutic proteins in stable cells with a Semliki Forest virus noncytopathic vector. N Biotechnol. 2010; 27:138–48. https://doi.org/10.1016/j.nbt.2010.02.005 PMID: 20188220
8. Lundstrom K. Expression of mammalian membrane proteins in mammalian cells using Semliki Forest virus vectors. Methods Mol Biol. 2010; 601:149–163. https://doi.org/10.1007/978-1-60761-344-2_10 PMID: 20099145
9. Nivitchanyong T, Tsai YC, Betenbaugh MJ, Oyler GA. An improved in vitro and in vivo Sindbis virus expression system through host and virus engineering. Virus Res. 2009; 141:1–12. https://doi.org/10.1016/j.virusres.2008.12.019 PMID: 19200810
10. Gehrke R, Heinz FX, Davis NL, Mandl CW. Heterologous gene expression by infectious and replicon vectors derived from tick-borne encephalitis virus and direct comparison of this flavivirus system with an alphavirus replicon. J Gen Virol. 2005; 86:1045–1053. https://doi.org/10.1099/vir.0.80677-0 PMID: 15784898
11. Yoshioka N, Gros E, Li HR, Kumar S, Deacon DC, Maron C, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell. 2013; 13:246–254. https://doi.org/10.1016/j.stem.2013.06.001 PMID: 23910086
12. Lundstrom K. Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim Biophys Acta. 2003; 1610:90–96. PMID: 12586383
13. Kawaguchi S, Ishiguro Y, Imaizumi T, Mori F, Matsumiya T, Yoshida H et al. Retinoic acid-inducible gene-I is constitutively expressed and involved in IFN-gamma-stimulated CXCL9-11 production in intestinal epithelial cells. Immunol Lett. 2009; 123:9–13. https://doi.org/10.1016/j.imlet.2009.01.008 PMID: 19201382
14. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol. 2008; 89:1–47. https://doi.org/10.1099/vir.0.83391-0 PMID: 18089727
15. Cruz CC, Suthar MS, Montgomery SA, Shabman R, Simmons J, Johnston RE, et al. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology. 2010; 399:1–10. https://doi.org/10.1016/j.virol.2009.12.031 PMID: 20097400
16. Frolov I, Akhrymuk M, Akhrymuk I, Atasheva S, Frolova EI. Early events in alphavirus replication determine the outcome of infection. J Virol. 2012; 86:5055–5066. https://doi.org/10.1128/JVI.07223-11 PMID: 22345447
17. Gardner CL, Yin J, Burke CW, Klimstra WB, Ryman KD. Type I interferon induction is correlated with attenuation of a South American eastern equine encephalitis virus strain in mice. Virology. 2009; 390:338–47. https://doi.org/10.1016/j.virol.2009.05.030 PMID: 19539968
18. Zhang Y, Burke CW, Ryman KD, Klimstra WB. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J Virol. 2007; 81:11246–11255. https://doi.org/10.1128/JVI.01282-07 PMID: 17686841
19. Konopka JL, Thompson JM, Whitmore AC, Webb DL, Johnston RE. Acute infection with Venezuelan equine encephalitis virus replicon particles catalyzes a systemic antiviral state and protects from lethal virus challenge. J Virol. 2009; 83:12432–12442. https://doi.org/10.1128/JVI.00564-09 PMID: 19793821
20. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem. 1995; 270:15974–15978. PMID: 7608155
21. Meyers JA, Mangini AJ, Nagai T, Roff CF, Sehy D, van Seventer GA, et al. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine. 2006; 35:235–246. https://doi.org/10.1016/j.cyto.2006.09.001 PMID: 17052915
22. Vancova I, La Bonnardiere C, Kontsek P. Vaccinia virus protein B18R inhibits the activity and cellular binding of the novel type interferon-delta. J Gen Virol. 1998; 79:1647–1649. https://doi.org/10.1099/0022-1317-79-7-1647 PMID: 9680126
23. Gomez AM, Ouellet M, Tremblay MJ. HIV-1-triggered release of type I IFN by plasmacytoid dendritic cells induces BAFF production in monocytes. J Immunol. 2015; 194:2300–2308. https://doi.org/10.4049/jimmunol.1402147 PMID: 25637018
24. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010; 7:618–630. https://doi.org/10.1016/j.stem.2010.08.012 PMID: 20888316
25. Quabius ES, Krupp G. Synthetic mRNAs for manipulating cellular phenotypes: an overview. N Biotechnol. 2015; 32:229–235. https://doi.org/10.1016/j.nbt.2014.04.008 PMID: 24816460
26. Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol. 2000; 74:11230–11239. PMID: 11070021
27. Liptakova H, Kontsekova E, Alcami A, Smith GL, Kontsek P. Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2. Virology. 1997; 232:86–90. PMID: 9185591
28. Fritz-French C, Shawahna R, Ward JE, Maroun LE, Tyor WR. The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model. J Interferon Cytokine Res. 2014; 34:510–517. https://doi.org/10.1089/jir.2013.0072 PMID: 24564363
29. Xiong AS, Yao QH, Peng RH, Li X, Fan HQ, Cheng ZM, et al. A simple, rapid, high-fidelity and cost-effective PCR-based two-step DNA synthesis method for long gene sequences. Nucleic Acids Res. 2004; 32(12):e98. https://doi.org/10.1093/nar/gnh094 PMID: 15240836
30. Petrakova O, Volkova E, Gorchakov R, Paessler S, Kinney RM, Frolov I. Noncytopathic replication of Venezuelan equine encephalitis virus and eastern equine encephalitis virus replicons in Mammalian cells. J Virol. 2005; 79:7597–7608. https://doi.org/10.1128/JVI.79.12.7597-7608.2005 PMID: 15919912
31. Frolov I, Agapov E, Hoffman TA, Pragai BM, Lippa M, Schlesinger S, et al. Selection of RNA replicons capable of persistent noncytopathic replication in mammalian cells. J Virol. 1999; 73:3854–3865. PMID: 10196280
32. Casales E, Rodriguez-Madoz JR, Ruiz-Guillen M, Razquin N, Cuevas Y, Prieto J,http://www. sciencedirect.com/science/article/pii/S004268220800189X-cor1 et al. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability. Virology. 2008; 376:242–251. https://doi.org/10.1016/j.virol.2008.03.016 PMID: 18442838
33. Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015; 33:58–63. https://doi.org/10.1038/nbt.3070 PMID: 25437882
34. Quetglas JI, Fioravanti J, Ardaiz N, Medina-Echeverz J, Baraibar I, Prieto J, et al.A Semliki forest virus vector engineered to express IFNalpha induces efficient elimination of established tumors. Gene Ther.2012; 19:271–278. https://doi.org/10.1038/gt.2011.99 PMID: 21734727
35. Phillips AT, Stauft CB, Aboellail TA, Toth AM, Jarvis DL, Powers AM, et al. Bioluminescent imaging and histopathologic characterization of WEEV neuroinvasion in outbred CD-1 mice. PLoS One.2013; 8: e53462. https://doi.org/10.1371/journal.pone.0053462 PMID: 23301074
36. Kümmerer BM, Grywna K, Glasker S, Wieseler J, Drosten C. Construction of an infectious Chikungunya virus cDNA clone and stable insertion of mCherry reporter genes at two different sites. J. Gen. Virol. 2012; 93:1991–1995. https://doi.org/10.1099/vir.0.043752-0 PMID: 22673932
37. Grieder FB, Vogel SN. Role of interferon and interferon regulatory factors in early protection against Venezuelan equine encephalitis virus infection. Virology.1999; 257:106–118. https://doi.org/10.1006/viro.1999.9662 PMID: 10208925
38. Spotts DR, Reich RM, Kalkhan MA, Kinney RM, Roehrig JT. Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5’noncoding region and glycoproteins. J. Virol. 1998; 72:10286–10291. PMID: 9811777
39. Hwang SY, Hetzog PJ, Holland KA, Sumarsono SH, Tymms MJ, Hamilton JA, et al. A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses. Proc. Natl. Acad. Sci. USA.1995; 92:11284–11288. PMID: 7479980
40. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al.Functional role of type I and type II interferons in antiviral defense. Science.1994; 264:1918–1921. PMID: 8009221
41. Ryman KD, Klimstra WB, Nguyen KB, Biron CA, Johnston RE. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J. Virol. 2000; 74:3366–3378. PMID: 10708454
42. Kunert R, Reinhart D. Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol. 2016; 100(8):3451–3461. https://doi.org/10.1007/s00253-016-7388-9 PMID: 26936774
43. Zhou S, Cerny AM, Zacharia A, Fitzgerald KA, Kurt-Jones EA, Finberg RW. Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus. J Virol. 2010; 84(18):9452–9462. https://doi.org/10.1128/JVI.00155-10 PMID: 20592086
44. Ho TH, Kew C, Lui PY, Chan CP, Satoh T, Akira S, et al.PACT- and RIG-I-Dependent activation of type I interferon production by a defective interfering RNA derived from measles virus vaccine.J Virol. 2015; 90(3):1557–1568. https://doi.org/10.1128/JVI.02161-15 PMID: 26608320